Skip to main content

Table 2 Characteristics of study participants from ROS/MAP (N = 2079) and ADNI1/GO/2 (N = 1419) after QC of genetic data

From: Genome-wide epistasis analysis for Alzheimer’s disease and implications for genetic risk prediction

ROS/MAP AD (n = 564) Non-ADa (n = 1515) Diff (P)b
 Sex (F/M) 388 F, 176 M 1060 F, 455 M 0.63
 Age at death, years (SD) 90.92 (5.88) 88.10 (6.73) < 0.0001
APOE ε4 status (−/+) − 378, + 186 (0.33) − 1226, + 289 (0.19) < 0.0001
ADNI AD (n = 555) Non-AD (n = 864) Diff (P)b
 Sex (F/M) 231 F, 324 M 372 F, 492 M 0.62
 Age at AD, years (SD) 74.78 (8.11) 77.49 (7.33) < 0.0001
APOE ε4 status (−/+) −201, + 354 (0.64) − 568, + 296 (0.34) < 0.0001
  1. ROS/MAP, The Religious Orders Study/the Rush Memory and Aging Project; ADNI, Alzheimer’s Disease Neuroimaging Initiative; AD, Alzheimer’s disease; Diff, the statistical difference between AD and non-AD; F, female; M, male; SD, standard deviation; Age at AD, age when AD developed for AD patients or age at last valid record for non-AD subjects; APOE ε4 status (−/+), presence of the ε4 allele
  2. aNon-AD in ROS/MAP includes 713 individuals with missing AD status
  3. bP values are calculated by Fisher’s exact tests (for sex and APOE ε4 status) or two-sample t tests (for age at death, age at AD)